<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483726</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0340</org_study_id>
    <nct_id>NCT04483726</nct_id>
  </id_info>
  <brief_title>Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)</brief_title>
  <acronym>DIPLOMA</acronym>
  <official_title>Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA): a Pan-European, Randomized Controlled, Multicenter, Patient Blinded, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal&#xD;
      adenocarcinoma (PDAC) in the pancreatic body or tail.&#xD;
&#xD;
      Study design: A pan-European, randomized controlled, multicenter, patient-blinded&#xD;
      non-inferiority trial. This protocol was designed according to the SPIRIT guidelines1.&#xD;
      Pathologists judging the primary endpoint will be blinded for the surgical approach (MIDP vs&#xD;
      ODP). A blinded adjudication committee will assess all endpoints.&#xD;
&#xD;
      Study population: Two groups of 129 patients (258 in total) with an indication for elective&#xD;
      distal pancreatectomy with splenectomy because of proven or highly suspected PDAC.&#xD;
&#xD;
      Intervention: Minimally invasive distal pancreatectomy (either laparoscopic or&#xD;
      robot-assisted)&#xD;
&#xD;
      Control: Open distal pancreatectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Several systematic reviews have suggested superior short term outcomes after&#xD;
      minimally invasive distal pancreatectomy (MIDP) as compared to open distal pancreatectomy&#xD;
      (ODP) for benign and pre-malignant disease. In the literature and in a recent pan-European&#xD;
      survey, about one third of pancreatic surgeons expressed concerns regarding the oncologic&#xD;
      safety (i.e. radical resection, lymph node retrieval and survival) of MIDP in pancreatic&#xD;
      cancer. Most surgeons stated that a randomized trial assessing oncologic safety in MIDP vs&#xD;
      ODP for pancreatic cancer is needed.&#xD;
&#xD;
      Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal&#xD;
      adenocarcinoma (PDAC) in the pancreatic body or tail.&#xD;
&#xD;
      Study design: A pan-European, randomized controlled, multicenter, patient-blinded&#xD;
      non-inferiority trial. This protocol was designed according to the SPIRIT guidelines1.&#xD;
      Pathologists judging the primary endpoint will be blinded for the surgical approach (MIDP vs&#xD;
      ODP). A blinded adjudication committee will assess all endpoints.&#xD;
&#xD;
      Study population: Two groups of 129 patients (258 in total) with an indication for elective&#xD;
      distal pancreatectomy with splenectomy because of proven or highly suspected PDAC.&#xD;
&#xD;
      Intervention: Minimally invasive distal pancreatectomy (either laparoscopic or&#xD;
      robot-assisted)&#xD;
&#xD;
      Control: Open distal pancreatectomy&#xD;
&#xD;
      Main study parameters/endpoints: Primary outcome is the microscopically radical (R0, &gt;1mm)&#xD;
      resection rate. Main secondary outcomes are survival, lymph node retrieval, intraoperative&#xD;
      outcomes (such as blood loss, operative time and conversion), postoperative outcomes (such as&#xD;
      complications, time to functional recovery and hospital stay) and quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">July 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 9, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microscopically radical resection rate</measure>
    <time_frame>1 day</time_frame>
    <description>R0, &gt;1mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>2 years</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>3 years</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymph node retrieval</measure>
    <time_frame>1 day</time_frame>
    <description>Tumor positive lymph nodes retrieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>1 day</time_frame>
    <description>Operative time from first incision to closure of the abdomen, minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>1 day</time_frame>
    <description>Intraoperative blood loss, mL (suction canister and weight of gauzes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative outcomes</measure>
    <time_frame>1 day</time_frame>
    <description>Total duration of the procedure, minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative outcomes</measure>
    <time_frame>1 day</time_frame>
    <description>Major complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>specimen size</measure>
    <time_frame>1 day</time_frame>
    <description>Tumor size, mm;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen length</measure>
    <time_frame>1 day</time_frame>
    <description>Specimen length, mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>margin</measure>
    <time_frame>1 day</time_frame>
    <description>Distance from tumor to transectionanterior and posterior margin mm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>MIDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minimally invasive distal pancreatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>open distal pancreatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>minimally invasive distal pancreatectomy</intervention_name>
    <description>Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)</description>
    <arm_group_label>MIDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open distal pancreatectomy</intervention_name>
    <description>open distal pancreatectomy</description>
    <arm_group_label>ODP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years;&#xD;
&#xD;
          -  Elective indication for distal pancreatectomy for proven or suspected* PDAC;&#xD;
&#xD;
          -  Upfront (without induction / down-sizing radio- and/or chemotherapy) resectable PDAC&#xD;
             in the pancreatic body or tail**;&#xD;
&#xD;
          -  The tumor can be radically resected via both minimally invasive or open surgery&#xD;
             according to the local treating team***;&#xD;
&#xD;
          -  The patient is fit to undergo both open and minimally invasive distal pancreatectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA &gt;3 (see appendix 17.3.2);&#xD;
&#xD;
          -  A medical history of chronic pancreatitis (according to the M-ANNHEIM criteria, see&#xD;
             Appendix for detailed definition);&#xD;
&#xD;
          -  Second malignancy necessitating resection during the same procedure;&#xD;
&#xD;
          -  Distant metastases (M1) including involved distant lymph nodes;&#xD;
&#xD;
          -  Tumor involvement or abutment of major vessels (celiac trunk*, mesenteric artery or&#xD;
             portomesenteric vein);&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Participation in another study with interference of study outcomes.&#xD;
&#xD;
          -  Cystic lesion having undergone malignant transformation&#xD;
&#xD;
               -  the celiac trunk should be 5mm clear from tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François Régis SOUCHE</last_name>
    <phone>+334 67 33 70 72</phone>
    <email>fr-souche@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillemette TACONNET</last_name>
    <phone>+334 67 33 55 73</phone>
    <email>g-taconnet_decker@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Beaujon - APHP</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Safi DOKMAK</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Eloi - Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Régis SOUCHE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier SAINT-MARC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David FUKS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio SA CUNHA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

